- Home
- HROW vs NBXG Comparison
HROW vs NBXG Comparison
Compare HROW & NBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- NBXG
- Stock Information
- Founded
- HROW 1998
- NBXG 2021
- Country
- HROW United States
- NBXG United States
- Employees
- HROW N/A
- NBXG N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- NBXG Trusts Except Educational Religious and Charitable
- Sector
- HROW Health Care
- NBXG Finance
- Exchange
- HROW Nasdaq
- NBXG Nasdaq
- Market Cap
- HROW 1.4B
- NBXG 1.1B
- IPO Year
- HROW N/A
- NBXG N/A
- Fundamental
- Price
- HROW $39.74
- NBXG N/A
- Analyst Decision
- HROW Strong Buy
- NBXG
- Analyst Count
- HROW 7
- NBXG 0
- Target Price
- HROW $68.50
- NBXG N/A
- AVG Volume (30 Days)
- HROW 889.7K
- NBXG 243.7K
- Earning Date
- HROW 11-12-2025
- NBXG 01-01-0001
- Dividend Yield
- HROW N/A
- NBXG 10.25%
- EPS Growth
- HROW N/A
- NBXG N/A
- EPS
- HROW N/A
- NBXG N/A
- Revenue
- HROW $227,661,000.00
- NBXG N/A
- Revenue This Year
- HROW $43.92
- NBXG N/A
- Revenue Next Year
- HROW $41.32
- NBXG N/A
- P/E Ratio
- HROW N/A
- NBXG N/A
- Revenue Growth
- HROW 47.69
- NBXG N/A
- 52 Week Low
- HROW $20.85
- NBXG $9.31
- 52 Week High
- HROW $59.23
- NBXG $12.23
- Technical
- Relative Strength Index (RSI)
- HROW 45.21
- NBXG 63.76
- Support Level
- HROW $40.79
- NBXG $15.37
- Resistance Level
- HROW $48.79
- NBXG $15.61
- Average True Range (ATR)
- HROW 2.41
- NBXG 0.16
- MACD
- HROW -0.87
- NBXG 0.00
- Stochastic Oscillator
- HROW 11.18
- NBXG 70.18
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in "NextGen Companies".